Search

--All CIT patients maintained platelet counts >75 x 10[sup.9]/L at 1-week following chemotherapy plus a single dose of SCB-219M, with durable responses through at least 3-weeks-- --Durable efficacy and PK [...]

Development program for VLX-1005, a novel small molecule 12-LOX inhibitor, awarded Fast Track designation by US Food and Drug Administration FREDERICK, Md., June 13, 2022 /PRNewswire/ -- Veralox Therapeutics, a [...]

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that its collaboration partner, Kissei Pharmaceutical Co., Ltd. ('Kissei'), has released positive topline results [...]

- Commercial Preparations Underway to Support Potential Approval and Launch of Pacritinib in the United States in 2021 - SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) [...]

Initiation of a Phase 1 clinical trial of VLX-1005 FREDERICK, Md., Jan. 14, 2021 /PRNewswire-PRWeb/ -- Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying [...]

- Completion of Submission Expected in First Quarter 2021 - - Pre-Commercialization Activities are Underway - SEATTLE, Oct. 13, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that [...]

STOCKHOLM, Oct. 9, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (STO:SOBI) today announced topline results from its phase 3 study of avatrombopag, an oral thrombopoietin (TPO) receptor agonist, [...]

SOUTH SAN FRANCISCO, Calif., July 27, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that a paper presenting a post-hoc data analysis of TAVALISSE(fostamatinib disodium hexahydrate) tablets, as [...]

PACIFICA Trial Protocol Amended to Allow for Primary Analysis of Spleen Volume Reduction (SVR) Rates on 168 Patients End of Study Analysis of Total Symptom Score (TSS) and Overall Survival [...]

Evidence-Based Guidelines to Drive Improved Care for Patients with ITP WASHINGTON, Dec. 3, 2019 /PRNewswire/ -- Today, ASH published new state-of-the art guidelines on the treatment of immune thrombocytopenia (ITP), [...]

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of [...]

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]

- Nearly 70% of patients maintained platelet counts of≥30�羅10[9]/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding - More than one-third of patients permanently stopped one [...]

Nplate Reduced Rates of Bleeding by More Than 30 Percent in Children Affected by Blood Disorder THOUSAND OAKS, Calif., April 19, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that The [...]

- Results published in the British Journal of Hematology - - BL-8040, currently in Phase 2 study for AML, continues to show promising results in other hematological indications - JERUSALEM, [...]